Not for human consumption, therapeutic, diagnostic or veterinary use
This is because it can increase transepidermal water loss and decrease hydration to disrupt the skin barrier
376 Da, 10 g/ml) and the transcellular marker Evans blue-albumin complex (EBA
Food and Drug Administration approved it as Mounjaro for type 2 diabetes in 2022 and as Zepbound for chronic weight management in 2023, and it is authorized by the European Medicines Agency as well
NAD IV therapy delivers a higher, more immediate dose over time, while injections are quicker, more convenient, and ideal for maintenance
In recent years, many non-traditional antifungal drugs have demonstrated the potential to inhibit and even kill invasive fungi (Farha and Brown, 2019)